Biotech and pharma companies often face a fork in the road where they must make a strategic directional decision to ensure value creation for shareholders and in some cases viability of the product or company. Although this happens fairly frequently in large, multinational companies, it is much more noticeable in small to mid-sized organizations where head counts and pipeline are much more concentrated. These decisions may involve a change of therapeutic focus, developing a device or platform instead of a drug, dropping other product development programs in order to focus on a priority product, downsizing, etc. Our panel of experts will discuss their own experiences in the art of the pivot and how these strategic moves, made at the right time and with the right leadership can be crucial to success.